Lupin launches tablet for bacterial infections in US


Pharma major Lupin has received FDA approval to market Doxycycline Hyclate Tablets ”used for the treatment of infections caused by various microorganisms ”available in 75 mg and 150 mg strength.

Lupins Doxycycline Hyclate Tablets USP, 75 mg and 150 mg are the AB-rated generic equivalent of Aqua Pharmaceuticals, LLCs Acticlate tablets, 75 mg and 150 mg. , Lupin said.

Doxycycline Hyclate Tablets is used for the treatment of a wide variety of bacterial infections, and as a complementary therapy in severe acne along with preventing malaria.


Lupins said that the tablets had annual sales of approximately US $ 263 million in the country until June 2017.


Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe Newsletter
To Top